Acrivon Therapeutics, Inc. 8-K Filing

Ticker: ACRV · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1781174

Acrivon Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAcrivon Therapeutics, Inc. (ACRV)
Form Type8-K
Filed DateSep 5, 2025
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Acrivon Therapeutics, Inc. (ticker: ACRV) to the SEC on Sep 5, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share ACRV The Nasdaq Stock Mar).

How long is this filing?

Acrivon Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 653 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-09-05 16:25:30

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ACRV The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 5, 2025, the Company posted to the "Investors & Media" section of the Company's website at ir.acrivon.com, a corporate presentation providing an update on the Company's business (the "Corporate Presentation"). This updated Corporate Presentation includes additional follow up syngeneic mouse model data where we observed continued strong synergy between each of our clinical candidates, ACR-368 and ACR-2316, with immune check point inhibitors. After multiple rounds of tumor implantations over almost one year, there is continued complete tumor regression and immune memory and we have further dissected which types of immune cells are responsible for the immune memory. This provides support for the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting. In addition, we have updated the pipeline overview slide to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial, which had been previously referenced, as well as updated information regarding our Generative Phosphoproteomics AP3 platform highlighting the capabilities of the platform in the generation of actionable, differentiated pathway-based insights for novel drug design and development. A Copy of the Corporate Presentation is attached hereto as Exhibit 99.1, and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Acrivon Therapeutics, Inc., Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Date: September 5, 2025 By: /s/ Peter Blume-Jensen Name: Peter Blume-Jensen, M.D., Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.